Dr. Bedrosian joined Ultragenyx in January 2018 as Chief Medical Officer and Executive Vice President. In this role, she provides strategic leadership to the clinical development and translational research programs, and oversees global development functions including: Medical, Clinical, Development Operations, Regulatory, Biometrics/CORE, Drug Safety/Pharmacovigilance, and Patient Advocacy and Engagement.

Prior to joining Ultragenyx, Dr. Bedrosian served nearly a decade as Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc. Prior to Alexion, Dr. Bedrosian spent more than five years as the Chief Medical Officer for ARIAD Pharmaceuticals, Inc., and earlier she served in the Clinical Research and Development Department of Genetics Institute, Inc. (acquired by Wyeth, now part of Pfizer). Previously, Dr. Bedrosian was an Assistant Professor of Medicine at Duke University Medical Center and a member of the Duke Comprehensive Cancer Center, where she completed her residency in internal medicine and a fellowship in hematology and medical oncology.

Dr. Bedrosian serves on the Board of Directors of Rhythm Pharmaceuticals and Crinetics Pharmaceuticals.
Dr. Bedrosian earned an A.B., magna cum laude, in honors chemistry from Harvard University, an M.D. from Harvard Medical School, and an M.S. in biophysics from the Massachusetts Institute of Technology (MIT). She currently serves as a member of the MIT Corporation Visiting Committee for the Department of Biology.